NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ: NAMS · HEALTHCARE · BIOTECHNOLOGY
$28.43
-1.01% today
Updated 2026-04-29
Market cap
$3.27B
P/E ratio
—
P/S ratio
145.26x
EPS (TTM)
$-1.72
Dividend yield
—
52W range
$17 – $42
Volume
0.9M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F7.3
Quality
B+2.5
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
3.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$49.39
+73.72%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.49 — safe zone
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-40.98M
- Revenue declining -99.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $102.69M | $14.09M | $45.56M | $22.50M | $22.50M |
| Net income | $-22.63M | $-176.94M | $-241.60M | $-203.82M | $-74.92M |
| EPS | — | — | — | — | $-1.72 |
| Free cash flow | $10.44M | $-141.24M | $-159.24M | $-148.03M | $-40.98M |
| Profit margin | -22.04% | -1,255.76% | -530.25% | -905.74% | — |
Peer comparison
Smart narrative
NewAmsterdam Pharma Company N.V. Ordinary Shares trades at $28.43. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.49, it sits in the safe zone. TTM revenue stands at $22.50M.
Frequently asked questions
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's stock price?
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) trades at $28.43.
Is NewAmsterdam Pharma Company N.V. Ordinary Shares overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell).
What is the price target of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)?
The analyst target price is $49.39, representing +73.7% upside from the current price of $28.43.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's revenue?
TTM revenue is $22.50M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.49 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio145.26x
ROE-28.30%
Beta0.13
50D MA$32.19
200D MA$31.62
Shares out0.11B
Float0.07B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—